Postpartum Depression Clinical Trials

DelveInsight’s analysis reveals that the Postpartum Depression pipeline includes over 10 key companies actively developing more than 10 treatment therapies for the condition.

Postpartum Depression Overview:

Postpartum depression (PPD) is a major health issue affecting around 15% of women following childbirth and can have significant adverse effects on their children. While the symptoms and risk factors of PPD are similar to those of general depression, it is specifically triggered by postpartum-related factors, particularly hormonal changes. Diagnosis is usually made in a clinical setting using standardized questionnaires.

Treatment typically involves psychotherapy and antidepressant medications. Symptoms of PPD resemble those seen in non-puerperal depression but occur in the context of recent childbirth. Common manifestations include persistent low mood, loss of interest, sleep and appetite disturbances, feelings of worthlessness, difficulty concentrating, and suicidal thoughts. Anxiety is also frequently observed. In severe cases, PPD may include psychotic symptoms, such as delusions or auditory hallucinations, sometimes involving voices instructing harm to the infant.

Request for a detailed insights report on Postpartum Depression pipeline insights

“Postpartum Depression Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Postpartum Depression Therapeutics Market.

Key Takeaways from the Postpartum Depression Pipeline Report

• DelveInsight’s Postpartum Depression pipeline report highlights an active landscape, with over three companies developing more than three pipeline therapies for the treatment of Postpartum Depression.

• Leading companies in this space, including GH Research, Reunion Neuroscience, Lipocine, Brii Biosciences Limited, and others, are exploring innovative therapies to enhance the available treatment options. Promising candidates in various stages of development include RE-104, GH001, BRII-297, among others.

• In August 2023, the U.S. Food and Drug Administration (FDA) approved Zurzuvae (zuranolone), representing the first oral therapy authorized for adults with postpartum depression (PPD). This approval marks a notable advancement over prior treatments, which were restricted to intravenous administration in clinical settings. Zurzuvae is a once-daily oral medication taken for 14 days, with patients often reporting symptom improvement as early as day three.

Postpartum Depression Pipeline Analysis

The report provides insights into:

• The report provides detailed insights into the key companies that are developing therapies in the Postpartum Depression Market.

• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Postpartum Depression treatment.

• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Postpartum Depression market.

Download our free sample page report on Postpartum Depression pipeline insights

Postpartum Depression Emerging Drugs

• RE-104: Reunion Neuroscience

• GH001: GH Research

• BRII-297: Brii Bio

Postpartum Depression Companies

More than 10 leading companies are actively working on therapies for postpartum depression, with Reunion Neuroscience having the most advanced candidate, currently in Phase II clinical trials.

DelveInsight’s report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Postpartum Depression pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Postpartum Depression Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Postpartum Depression Therapies and Key Companies: Postpartum Depression Clinical Trials and advancements

Postpartum Depression Pipeline Therapeutic Assessment

• Postpartum Depression Assessment by Product Type

• Postpartum Depression By Stage

• Postpartum Depression Assessment by Route of Administration

• Postpartum Depression Assessment by Molecule Type

Download Postpartum Depression Sample report to know in detail about the Postpartum Depression treatment market @ Postpartum Depression Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Postpartum Depression Current Treatment Patterns

4. Postpartum Depression – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Postpartum Depression Late-Stage Products (Phase-III)

7. Postpartum Depression Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Postpartum Depression Discontinued Products

13. Postpartum Depression Product Profiles

14. Postpartum Depression Key Companies

15. Postpartum Depression Key Products

16. Dormant and Discontinued Products

17. Postpartum Depression Unmet Needs

18. Postpartum Depression Future Perspectives

19. Postpartum Depression Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Postpartum Depression Pipeline Reports Offerings

Contact Info:

Kritika Rehani

krehani@delveinsight.com

+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/